Antiviral treatment for brain problems from congenital CMV
Part of Infections clinical trials.
This study looks at whether giving antiviral medicine for 4 to 6 months can help babies born with CMV infection who have brain or hearing problems. The medicine aims to reduce the long-term effects of the infection on development.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must have CMV (cytomegalovirus) confirmed by a test within 21 days after birth.
- The infection must be causing moderate to severe symptoms, such as hearing loss, a small head, or other brain-related signs.
- Your baby must be 30 days old or younger when joining the study.
- Your baby must have been born at 32 weeks or later (not very premature).
- Your baby must weigh at least 1.8 kg (about 4 pounds) at birth.
- You (the parent or guardian) must give written permission (informed consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow children born in New York State who were tested for cytomegalovirus (CMV) as newborns. It aims to understand their long-term health and development, whether they were confirmed to have CMV, a false positive, or even a late detection if born early.
This Phase 2 trial tests an immune treatment made from donor T-cells to help the body fight congenital CMV infection in newborns. It may be an option if your baby is very young, has evidence of CMV infection, and meets specific blood, kidney, and liver safety limits.
This is an observational study that looks at how babies with congenital CMV infection are diagnosed and managed in real life. It may help doctors understand which care approaches are used and how they relate to outcomes over time.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
This trial tests a treatment targeting a common virus (CMV) in breast cancer that has spread to the brain. The goal is to see if anti-CMV therapy can shrink or slow these brain tumors.
This trial tests whether valganciclovir, an antiviral medicine, can help people with advanced HIV who have CMV in their blood but no CMV disease. The goal is to see if the medicine can reduce the amount of CMV and improve health.
Hear when a new Congenital CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.